A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update Meeting Abstract
| Authors: | Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; O'Cearbhaill, R.; Bouberhan, S.; Moore, K.; Hou, J.; Hamilton, E.; Yoo, S. Y.; Wang, B.; Peterman, M.; Schmidt, T.; Knorr, D.; Lowy, I.; Uldrick, T.; Miller, E. |
| Abstract Title: | A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S284 |
| Language: | English |
| ACCESSION: | WOS:001330731400410 |
| DOI: | 10.1016/j.ygyno.2024.07.422 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2124 [TIP] -- Source: Wos |
